Skip to main content
. 2017 Nov 24;11(1):131–141. doi: 10.1007/s40271-017-0287-z

Fig. 4.

Fig. 4

Longitudinal analysis of all prespecified PROs symptoms of interest: cough, dyspnea, and pain by mutation type (Del19 and L858R). Scores range from 0 to 100 (100 is equivalent to the highest burden of symptoms and 0 to the lowest burden); mean treatment difference shown as afatinib minus chemotherapy and, as such, a negative score favors afatinib treatment. CI, confidence interval; PRO, patient-reported outcome